Aluminum vaccine adjuvants: Are they safe?

Current Medicinal Chemistry

Volumn 18, Issue 17, 2011, Pages 2630-2637

  Tomljenovic, L ^a   Shaw, C A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adjuvant safety; Aluminum adjuvants; Autism; Autoimmunity; Gulf War Syndrome; Macrophagic myofasciitis; Multiple sclerosis; Neurotoxicity; Seizures; Th2 immune response; Vaccines

Indexed keywords

ADJUVANT; ALUMINUM; ALUMINUM CHLORIDE; ALUMINUM HYDROXIDE; ALUMINUM LACTATE; ALUMINUM OXIDE; ALUMINUM PHOSPHATE; ALUMINUM SULFATE; ANTACID AGENT; ANTHRAX VACCINE; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; VACCINE;

ALUMINUM OVERLOAD; ANXIETY DISORDER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BEHAVIOR DISORDER; BRAIN ISCHEMIA; COGNITIVE DEFECT; CONCENTRATION LOSS; CRANIOFACIAL SYNOSTOSIS; DEMENTIA; DRUG FATALITY; DRUG RESEARCH; DRUG SAFETY; ENCEPHALITIS; ENVIRONMENTAL EXPOSURE; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPATHOLOGY; INSOMNIA; IRRITABILITY; MENTAL INSTABILITY; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROTOXICITY; NONHUMAN; PERSIAN GULF SYNDROME; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SPEECH DISORDER; TH2 CELL; TOXICOKINETICS; VASCULAR AMYLOIDOSIS; VISUAL HALLUCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM; ANIMALS; ANTHRAX VACCINES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BODY BURDEN; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; PLACEBOS; VACCINES;

EID: 79957951065     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795933740     Document Type: Article

References (116)

1. Exley, C.; Siesjo, P.; Eriksson, H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010, 31(3), 103-109.
2. Eickhoff, T.C.; Myers, M. Workshop summary. Aluminum in vaccines. Vaccine. 2002, 20 Suppl 3, S1-4.
3. Offit, P.A.; Jew, R.K. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 2003, 112(6 Pt 1), 1394-1397.
4. Cribbs, D.H.; Ghochikyan, A.; Vasilevko, V.; Tran, M.; Petrushina, I.; Sadzikava, N.; Babikyan, D.; Kesslak, P.; Kieber-Emmons, T.; Cotman, C.W.; Agadjanyan, M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003, 15(4), 505-514. (Pubitemid 36432403)
5. Shoenfeld, Y.; Agmon-Levin, N. 'ASIA' - Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011, 36(1), 4-8.
6. Israeli, E.; Agmon-Levin, N.; Blank, M.; Shoenfeld, Y. Adjuvants and autoimmunity. Lupus. 2009, 18(13), 1217-1225.
7. Exley, C.; Swarbrick, L.; Gherardi, R.K.; Authier, F.J. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses. 2009, 72(2), 135-139.
8. Gherardi, R.K. [Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome]. Rev Neurol (Paris). 2003, 159(2), 162-164. (Pubitemid 36292557)
9. Centers for Disease Control and Prevention (CDC). 2010 Child & Adolescent Immunization Schedules for persons aged 0-6 years, 7-18 years, and "catch-up schedule" and Past Childhood Immunization Schedules. http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm#chgs (Accessed September 2, 2010).
10. U.K. Department of Health. Immunisation against infectious disease - "The Green Book", Part 1 Principles, practices and procedures, Chapter 11: Immunisation schedule. 2007. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH-079917 (Accessed August 19, 2010).
11. Tomljenovic, L. Aluminum and Alzheimer's disease: after a century of controversy, is there a plausible link? J Alzheimers Dis. 2011, 23(4), 567-598.
12. Exley, C. Aluminium and Medicine. In Molecular and Supramolecular Bioinorganic Chemistry: Applications in Medical Sciences. Merce, A.L.R.; Felcman, J.; Recio, M.A.L., Eds.; Nova Biomedical Books: New York. 2009, pp. 45-68.
13. Eldred, B.E.; Dean, A.J.; McGuire, T.M.; Nash, A.L. Vaccine components and constituents: responding to consumer concerns. Med J Aust. 2006, 184(4), 170-175.
14. Centers for Disease Control and Prevention (CDC). Guide to Vaccine Contraindications and Precautions. http://www.cdc.gov/vaccines/recs/vacadmin/ downloads/contraindications-guide-508.pdf (Accessed November 22, 2010).
15. Jefferson, T.; Rudin, M.; Di Pietrantonj, C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis. 2004, 4(2), 84-90. (Pubitemid 38169274)
16. Agency for toxic substances and disease registry (ATSDR) Toxicological profile for aluminum. Atlanta, GA, 2008, pp.1-357. http://www.atsdr.cdc.gov/ toxprofiles/tp22.html (Accessed July 20, 2010).
17. Gies, W.J. Some objections to the use of alum baking-powder. JAMA. 1911, 57(10), 816-821.
18. Walton, J.R. A longitudinal study of rats chronically exposed to aluminum at human dietary levels. Neurosci Lett. 2007, 412(1), 29-33. (Pubitemid 46038549)
19. Walton, J.R. Functional impairment in aged rats chronically exposed to human range dietary aluminum equivalents. Neurotoxicology. 2009, 30(2), 182-193.
20. Wills, M.R.; Savory, J. Water content of aluminum, dialysis dementia, and osteomalacia. Environ Health Perspect. 1985, 63, 141-147. (Pubitemid 16179344)
21. Flendrig, J.A.; Kruis, H.; Das, H.A. Aluminium intoxication: the cause of dialysis dementia ? Proc Eur Dial Transplant Assoc. 1976, 13, 355-368.
22. Altmann, P. In Aluminium and Alzheimer's Disease: The science that describes the link. Exley, C., Ed.; Elsevier Science: Amsterdam. 2001, pp. 1-37.
23. D'Haese, P.C.; Couttenye, M.M.; De Broe, M.E. Diagnosis and treatment of aluminium bone disease. Nephrol Dial Transplant. 1996, 11 Suppl 3, 74-79. (Pubitemid 26278593)
24. Alfrey, A.C. Dialysis encephalopathy syndrome. Annu Rev Med. 1978, 29, 93-98.
25. Alfrey, A.C. Dialysis encephalopathy. Kidney Int Suppl. 1986, 18, S53-57.
26. Alfrey, A.C.; LeGendre, G.R.; Kaehny, W.D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976, 294(4), 184-188.
27. Rozas, V.V.; Port, F.K.; Easterling, R.E. An outbreak of dialysis dementia due to aluminum in the dialysate. J Dial. 1978, 2(5-6), 459-470. (Pubitemid 9134695)
28. Exley, C. Aluminium and Alzheimer's Disease: The science that describes the link, 1st ed.; Elsevier Science: Amsterdam. 2001.
29. Perl, D.P.; Moalem, S. Aluminum and Alzheimer's disease, a personal perspective after 25 years. J Alzheimers Dis. 2006, 9(3 Suppl), 291-300. (Pubitemid 44253322)
30. Exley, C.; Mamutse, G.; Korchazhkina, O.; Pye, E.; Strekopytov, S.; Polwart, A.; Hawkins, C. Elevated urinary excretion of aluminium and iron in multiple sclerosis. Mult Scler. 2006, 12(5), 533-540. (Pubitemid 46940625)
31. Blaylock, R.L.; Strunecka, A. Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders. Curr Med Chem. 2009, 16(2), 157-170.
32. Bishop, N.J.; Morley, R.; Day, J.P.; Lucas, A. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. N Engl J Med. 1997, 336(22), 1557-1561. (Pubitemid 27231156)
33. Pivnick, E.K.; Kerr, N.C.; Kaufman, R.A.; Jones, D.P.; Chesney, R.W. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin Pediatr (Phila). 1995, 34(2), 73-78.
34. Exley, C.; Esiri, M.M. Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK. J Neurol Neurosurg Psychiatry. 2006, 77(7), 877-879. (Pubitemid 44023186)
35. Bowdler, N.C.; Beasley, D.S.; Fritze, E.C.; Goulette, A.M.; Hatton, J.D.; Hession, J.; Ostman, D.L.; Rugg, D.J.; Schmittdiel, C.J. Behavioral effects of aluminum ingestion on animal and human subjects. Pharmacol Biochem Behav. 1979, 10(4), 505-512. (Pubitemid 9182932)
36. Sinczuk-Walczak, H.; Szymczak, M.; Razniewska, G.; Matczak, W.; Szymczak, W. Effects of occupational exposure to aluminum on nervous system: clinical and electroencephalographic findings. Int J Occup Med Environ Health. 2003, 16(4), 301-310. (Pubitemid 38141866)
37. Wisniewski, H.M.; Sturman, J.A.; Shek, J.W. Chronic model of neurofibrillary changes induced in mature rabbits by metallic aluminum. Neurobiol Aging. 1982, 3(1), 11-22. (Pubitemid 12066361)
38. Klatzo, I.; Wisniewski, H.; Streicher, E. Experimental Production of Neurofibrillary Degeneration. I. Light Microscopic Observations. J Neuropathol Exp Neurol. 1965, 24, 187-199.
39. McLachlan, D.R.C.; Dalton, A.J. Alterations in short-term retention, conditioned avoidance response acquisition and motivation following aluminum induced neurofibrillary degeneration. Physiol Behav. 1973, 10(5), 925-933.
40. McLachlan, D.C. Experimental neurofibrillary degeneration and altered electrical activity. Electroencephalogr Clin Neurophysiol. 1973, 35(6), 575-588.
41. Pendlebury, W.W.; Beal, M.F.; Kowall, N.W.; Solomon, P.R. Neuropathologic, neurochemical and immunocytochemical characteristics of aluminum-induced neurofilamentous degeneration. Neurotoxicology. 1988, 9(3), 503-510.
42. Petit, T.L.; Biederman, G.B.; McMullen, P.A. Neurofibrillary degeneration, dendritic dying back, and learning-memory deficits after aluminum administration: implications for brain aging. Exp Neurol. 1980, 67(1), 152-162. (Pubitemid 10172200)
43. Petrik, M.S.; Wong, M.C.; Tabata, R.C.; Garry, R.F.; Shaw, C.A. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromolecular Med. 2007, 9(1), 83-100. (Pubitemid 44772277)
44. Shaw, C.A.; Petrik, M.S. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. J Inorg Biochem. 2009, 103(11), 1555-1562.
45. Walton, J.R.; Wang, M.X. APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer's disease. J Inorg Biochem. 2009, 103(11), 1548-1554.
46. Golub, M.S.; Gershwin, M.E.; Donald, J.M.; Negri, S.; Keen, C.L. Maternal and developmental toxicity of chronic aluminum exposure in mice. Fundam Appl Toxicol. 1987, 8(3), 346-357. (Pubitemid 17056165)
47. Waly, M.; Olteanu, H.; Banerjee, R.; Choi, S.W.; Mason, J.B.; Parker, B.S.; Sukumar, S.; Shim, S.; Sharma, A.; Benzecry, J.M.; Power-Charnitsky, V.A.; Deth, R.C. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry. 2004, 9(4), 358-370. (Pubitemid 38534697)
48. Villa, L.L.; Costa, R.L.; Petta, C.A.; Andrade, R.P.; Ault, K.A.; Giuliano, A.R.; Wheeler, C.M.; Koutsky, L.A.; Malm, C.; Lehtinen, M.; Skjeldestad, F.E.; Olsson, S.E.; Steinwall, M.; Brown, D.R.; Kurman, R.J.; Ronnett, B.M.; Stoler, M.H.; Ferenczy, A.; Harper, D.M.; Tamms, G.M.; Yu, J.; Lupinacci, L.; Railkar, R.; Taddeo, F.J.; Jansen, K.U.; Esser, M.T.; Sings, H.L.; Saah, A.J.; Barr, E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005, 6(5), 271-278. (Pubitemid 40590263)
49. Harper, D.M.; Franco, E.L.; Wheeler, C.; Ferris, D.G.; Jenkins, D.; Schuind, A.; Zahaf, T.; Innis, B.; Naud, P.; De Carvalho, N.S.; Roteli-Martins, C.M.; Teixeira, J.; Blatter, M.M.; Korn, A.P.; Quint, W.; Dubin, G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004, 364(9447), 1757-1765. (Pubitemid 39488060)
50. Verstraeten, T.; Descamps, D.; David, M.P.; Zahaf, T.; Hardt, K.; Izurieta, P.; Dubin, G.; Breuer, T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008, 26(51), 6630-6638.
51. Garland, S.M.; Hernandez-Avila, M.; Wheeler, C.M.; Perez, G.; Harper, D.M.; Leodolter, S.; Tang, G.W.; Ferris, D.G.; Steben, M.; Bryan, J.; Taddeo, F.J.; Railkar, R.; Esser, M.T.; Sings, H.L.; Nelson, M.; Boslego, J.; Sattler, C.; Barr, E.; Koutsky, L.A. (FUTURE) I Investigators) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007, 356(19), 1928-1943. (Pubitemid 46740303)
52. Food and Drug Administration. Inside Clinical Trials: Testing Medical Products in People. Last updated May 2009. http://www.fda.gov/Drugs/ ResourcesForYou/Consumers/ucm143531.htm (Accessed April 4, 2011).
53. Sanofi Pasteur MSD Limited. Revaxis: Summary of Product Characteristics. 2008. http://www.medicines.org.uk/emc/document.aspx?documentid=15259 (Accessed November 17, 2010).
54. Zheng, W. Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol. 2001, 39(7), 711-719. (Pubitemid 34016566)
55. Blaylock, R.L. Excitotoxicity: a possible central mechanism in fluoride neurotoxicity. Fluoride. 2004, 37(4), 264-277.
56. Food and Drug Administration (FDA) Department of Health and Human Services. Aluminum in large and small volume parenterals used in total parenteral nutrition, amendment June 2003, pp. 74. http://edocket.access.gpo. gov/cfr-2005/aprqtr/pdf/21cfr201.323.pdf (Accessed August 23, 2010).
57. Public Health Agency of Canada. Immunization Schedules for Infants and Children, source: Canadian Immunization Guide, Seventh Edition. 2006. http://www.phac-aspc.gc.ca/im/is-cv/ (Accessed September 2, 2010).
58. Australian Government Department of Health and Aging. National Immunisation Program (NIP) Schedule. http://immunise.health.gov.au/internet/ immunise/publishing.nsf/Content/nips 2 (Accessed September 2, 2010).
59. Bioport Corp. Anthrax Vaccine Adsorbed (Biothrax™), product monograph. 2002, pp. 1-7. http://www.fda.gov/OHRMS/DOCKETS/98fr/05n-0040- bkg0001.pdf (Accessed September 2, 2010).
60. Haddad, S.; Restieri, C.; Krishnan, K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J Toxicol Environ Health A. 2001, 64(6), 453-464. (Pubitemid 33139645)
61. Golub, M.S.; Donald, J.M.; Gershwin, M.E.; Keen, C.L. Effects of aluminum ingestion on spontaneous motor activity of mice. Neurotoxicol Teratol. 1989, 11(3), 231-235. (Pubitemid 19184111)
62. Domingo, J.L.; Gomez, M.; Bosque, M.A.; Corbella, J. Lack of teratogenicity of aluminum hydroxide in mice. Life Sci. 1989, 45(3), 243-247. (Pubitemid 19172565)
63. Domingo, J.L.; Gómez, M.; Colomina, M.T. Risks of aluminium exposure during pregnancy. Contrib Sci. 2000, 1(4), 479-487.
64. Benett, R.W.; Persaud, T.V.; Moore, K.L. Experimental studies on the effects of aluminium on pregnancy and fetal development. Anat Anz. 1975, 138, 365-378.
65. Bernuzzi, V.; Desor, D.; Lehr, P.R. Developmental alternations in offspring of female rats orally intoxicated by aluminum chloride or lactate during gestation. Teratology. 1989, 40(1), 21-27. (Pubitemid 19190548)
66. Clayton, R.M.; Sedowofia, S.K.; Rankin, J.M.; Manning, A. Long-term effects of aluminium on the fetal mouse brain. Life Sci. 1992, 51(25), 1921-1928.
67. Rankin, J.; Sedowofia, K.; Clayton, R.; Manning, A. Behavioural effects of gestational exposure to aluminium. Ann Ist Super Sanita. 1993, 29(1), 147-152.
68. Poulos, B.K.; Perazzolo, M.; Lee, V.M.; Rudelli, R.; Wisniewski, H.M.; Soifer, D. Oral aluminum administration during pregnancy and lactation produces gastric and renal lesions in rat mothers and delay in CNS development of their pups. Mol Chem Neuropathol. 1996, 29(1), 15-26. (Pubitemid 26327479)
69. Alleva, E.; Rankin, J.; Santucci, D. Neurobehavioral alteration in rodents following developmental exposure to aluminum. Toxicol Ind Health. 1998, 14(1-2), 209-221. (Pubitemid 28044976)
70. Llansola, M.; Minana, M.D.; Montoliu, C.; Saez, R.; Corbalan, R.; Manzo, L.; Felipo, V. Prenatal Exposure to Aluminum Reduces Expression of Neuronal Nitric Oxide Synthase and of Soluble Guanylate Cyclase and Impairs Glutamatergic Neurotransmission in Rat Cerebellum. J Neurochem. 1999, 73, 712-718. (Pubitemid 29339845)
71. Wang, M.; Chen, J.T.; Ruan, D.Y.; Xu, Y.Z. The influence of developmental period of aluminum exposure on synaptic plasticity in the adult rat dentate gyrus in vivo. Neuroscience. 2002, 113(2), 411-419. (Pubitemid 34786186)
72. Gonda, Z.; Lehotzky, K.; Miklosi, A. Neurotoxicity induced by prenatal aluminum exposure in rats. Neurotoxicology. 1996, 17(2), 459-469.
73. Yokel, R.A.; Hicks, C.L.; Florence, R.L. Aluminum bioavailability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese. Food Chem Toxicol. 2008, 46(6), 2261-2266.
74. Yokel, R.A.; McNamara, P.J. Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol. 2001, 88(4), 159-167. (Pubitemid 32322847)
75. GlaxoSmithKline. Boostrix product monograph, Combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine for boosternvaccination. Date of Approval: October 21, 2009. http://www.gsk.ca/english/docspdf/ Boostrix-PM-20091021-EN.pdf (Accessed August 11, 2010).
76. Makidon, P.E.; Bielinska, A.U.; Nigavekar, S.S.; Janczak, K.W.; Knowlton, J.; Scott, A.J.; Mank, N.; Cao, Z.; Rathinavelu, S.; Beer, M.R.; Wilkinson, J.E.; Blanco, L.P.; Landers, J.J.; Baker, J.R., Jr. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One. 2008, 3(8), e2954.
77. Redhead, K.; Quinlan, G.J.; Das, R.G.; Gutteridge, J.M. Aluminiumadjuvanted vaccines transiently increase aluminium levels in murine brain tissue. Pharmacol Toxicol. 1992, 70(4), 278-280.
78. Levy, R.; Shohat, L.; Solomon, B. Specificity of an anti-aluminium monoclonal antibody toward free and protein-bound aluminium. J Inorg Biochem. 1998, 69(3), 159-163. (Pubitemid 28270143)
79. Flarend, R.E.; Hem, S.L.; White, J.L.; Elmore, D.; Suckow, M.A.; Rudy, A.C.; Dandashli, E.A. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine. 1997, 15(12-13), 1314-1318. (Pubitemid 27397805)
80. Yumoto, S.; Nagai, H.; Matsuzaki, H.; Kobayashi, T.; Tada, W.; Ohki, Y.; Kakimi, S.; Kobayashi, K. Transplacental passage of 26Al from pregnant rats to fetuses and 26Al transfer through maternal milk to suckling rats Nucl Instrum Methods Phys Res B. 2000, 172(1-4), 925-929. (Pubitemid 32067476)
81. Wyeth Canada. Meningitec product monograph. Date of last approval 2007, pp. 1-29. http://www.wyeth.ca/en/products/Product%20Monographs% 20PDFs/Meningitec-PM.pdf (Accessed September 2, 2010).
82. Centers for Disease Control and Prevention (CDC). Recommended Adult Immunization Schedule - United States, 2010. http://www.cdc.gov/mmwr/PDF/wk/ mm5901-Immunization.pdf (Accessed September 15, 2010).
83. Authier, F.J.; Cherin, P.; Creange, A.; Bonnotte, B.; Ferrer, X.; Abdelmoumni, A.; Ranoux, D.; Pelletier, J.; Figarella-Branger, D.; Granel, B.; Maisonobe, T.; Coquet, M.; Degos, J.D.; Gherardi, R.K. Central nervous system disease in patients with macrophagic myofasciitis. Brain. 2001, 124(Pt 5), 974-983. (Pubitemid 32458509)
84. Gherardi, R.K.; Coquet, M.; Cherin, P.; Authier, F.J.; Laforet, P.; Belec, L.; Figarella-Branger, D.; Mussini, J.M.; Pellissier, J.F.; Fardeau, M. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet. 1998, 352(9125), 347-352.
85. Gherardi, R.K.; Coquet, M.; Cherin, P.; Belec, L.; Moretto, P.; Dreyfus, P.A.; Pellissier, J.F.; Chariot, P.; Authier, F.J. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001, 124(Pt 9), 1821-1831. (Pubitemid 32845443)
86. Authier, F.J.; Sauvat, S.; Christov, C.; Chariot, P.; Raisbeck, G.; Poron, M.F.; Yiou, F.; Gherardi, R. AlOH3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background. Neuromuscul Disord. 2006, 16(5), 347-352.
87. Holt, P.G.; Upham, J.W.; Sly, P.D. Contemporaneous maturation of immunologic and respiratory functions during early childhood: implications for development of asthma prevention strategies. J Allergy Clin Immunol. 2005, 116,(1), 16-24.
88. Romagnani, S. Biology of human TH1 and TH2 cells. J Clin Immunol. 1995, 15(3), 121-129.
89. Elenkov, I.J.; Chrousos, G.P. Stress Hormones, Th1/Th2 patterns, Pro/Antiinflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol Metab. 1999, 10(9), 359-368. (Pubitemid 29496010)
90. Wrensch, M.; Weinberg, A.; Wiencke, J.; Miike, R.; Sison, J.; Wiemels, J.; Barger, G.; DeLorenze, G.; Aldape, K.; Kelsey, K. History of chickenpox and shingles and prevalence of antibodies to varicella-zoster viru s and three other herpesviruses among adults with glioma and controls. Am J Epidemiol. 2005, 161, 929-938. (Pubitemid 40656415)
91. Silverberg, J.I.; Norowitz, K.B.; Kleiman, E.; Durkin, H.G.; Smith-Norowitz, T.A. Varicella zoster virus (wild-type) infection, but not varicella vaccine, in late childhood is associated with delayed asthma onset, milder symptoms, and decreased atopy. Pediatr Asthma Allergy Immunol.2009, 22, 15-20.
92. Silverberg, J.I.; Norowitz, K.B.; Kleiman, E.; Silverberg, N.B.; Durkin, H.G.; Joks, R.; Smith-Norowitz, T.A. Association between varicella zoster virus infection and atopic dermatitis in early and late childhood: a casecontrol study. J Allergy Clin Immunol. 2010, 126, 300-305.
93. Sasco, A.J.; Paffenbarger, R.S., Jr. Measles infection and Parkinson's disease. Am J Epidemiol. 1985, 122(6), 1017-1031. (Pubitemid 16170037)
94. GlaxoSmithKline. Engerix-B product monograph. 2010, pp. 1-14. http://us.gsk.com/products/assets/us-engerixb.pdf (Accessed September 20, 2010).
95. Schurmans, S.; Heusser, C.H.; Qin, H.Y.; Merino, J.; Brighouse, G.; Lambert, P.H. In vivo effects of anti-IL-4 monoclonal antibody on neonatal induction of tolerance and on an associated autoimmune syndrome. J Immunol. 1990, 145, 2465-2473. (Pubitemid 20374565)
96. Fournie, G.J.; Mas, M.; Cautain, B.; Savignac, M.; Subra, J.F.; Pelletier, L.; Saoudi, A.; Lagrange, D.; Calise, M.; Druet, P. Induction of autoimmunity through bystander effects. Lessons from immunological disorders induced by heavy metals. J Autoimmun. 2001, 16, 319-326. (Pubitemid 32566121)
97. EMEA. Hexavac, scientific discussion. 2004, pp. 1-33. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- -Scientific- Discussion/human/000298/WC500074582.pdf (Accessed October 12, 2010).
98. Zinka, B.; Rauch, E.; Buettner, A.; Rueff, F.; Penning, R. Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine. 2006, 24(31-32), 5779-5780. (Pubitemid 43947382)
99. Banks, W.A.; Kastin, A.J. Aluminum-induced neurotoxicity: alterations in membrane function at the blood-brain barrier. Neurosci Biobehav Rev. 1989, 13(1), 47-53. (Pubitemid 19215169)
100. Li, X.; Zheng, H.; Zhang, Z.; Li, M.; Huang, Z.; Schluesener, H.J.; Li, Y.; Xu, S. Glia activation induced by peripheral administration of aluminum oxide nanoparticles in rat brains. Nanomed Nanotech Biol Med. 2009, 5(4), 473-479.
101. Campbell, A. Inflammation, neurodegenerative diseases, and environmental exposures. Ann N Y Acad Sci. 2004, 1035, 117-132. (Pubitemid 40362330)
102. Garrel, C.; Lafond, J.L.; Guiraud, P.; Faure, P.; Favier, A. Induction of production of nitric oxide in microglial cells by insoluble form of aluminium. Ann N Y Acad Sci. 1994, 738, 455-461.
103. Struys-Ponsar, C.; Guillard, O.; van den Bosch de Aguilar, P. Effects of aluminum exposure on glutamate metabolism: a possible explanation for its toxicity. Exp Neurol. 2000, 163(1), 157-164. (Pubitemid 30314370)
104. Tsunoda, M.; Sharma, R.P. Modulation of tumor necrosis factor alpha expression in mouse brain after exposure to aluminum in drinking water. Arch Toxicol. 1999, 73(8-9), 419-426. (Pubitemid 30010242)
105. Block, M.L.; Hong, J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005, 76(2), 77-98. (Pubitemid 41242883)
106. Lukiw, W.J.; Bazan, N.G. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem Res. 2000, 25(9-10), 1173-1184.
107. Campbell, A.; Becaria, A.; Lahiri, D.K.; Sharman, K.; Bondy, S.C. Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain. J Neurosci Res. 2004, 75(4), 565-572. (Pubitemid 38160717)
108. Cohly, H.H.; Panja, A. Immunological findings in autism. Int Rev Neurobiol. 2005, 71, 317-341. (Pubitemid 43580939)
109. Vargas, D.L.; Nascimbene, C.; Krishnan, C.; Zimmerman, A.W.; Pardo, C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005, 57(1), 67-81. (Pubitemid 40053317)
110. Pardo, C.A.; Vargas, D.L.; Zimmerman, A.W. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 2005, 17(6), 485-495. (Pubitemid 43086675)
111. Shirabe, T.; Irie, K.; Uchida, M. Autopsy case of aluminum encephalopathy. Neuropathology. 2002, 22(3), 206-210. (Pubitemid 35252712)
112. Platt, B.; Fiddler, G.; Riedel, G.; Henderson, Z. Aluminium toxicity in the rat brain: histochemical and immunocytochemical evidence. Brain Res Bull. 2001, 55(2), 257-267. (Pubitemid 32722168)
113. Alexandrov, P.N.; Zhao, Y.; Pogue, A.I.; Tarr, M.A.; Kruck, T.P.; Percy, M.E.; Cui, J.G.; Lukiw, W.J. Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005, 8(2), 117-127; discussion 209-115. (Pubitemid 43227158)
114. Lukiw, W.J.; Percy, M.E.; Kruck, T.P. Nanomolar aluminum induces proinflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem. 2005, 99(9), 1895-1898. (Pubitemid 41253779)
115. Pogue, A.I.; Li, Y.Y.; Cui, J.G.; Zhao, Y.; Kruck, T.P.; Percy, M.E.; Tarr, M.A.; Lukiw, W.J. Characterization of an NF-kappaB-regulated, miRNA- 146a-mediated down-regulation of complement factor H (CFH) in metalsulfate- stressed human brain cells. J Inorg Biochem. 2009, 103(11), 1591-1595.
116. Lukiw, W.J. In Aluminium and Alzheimer's Disease: The science that describes the link. Exley, C., Ed.; Elsevier Science: Amsterdam. 2001, pp. 147-169.